Marcus Müller

Marcus Müller

Auto-generated profile, based on publicly available information

Marcus Müller

Department of Neurology, Universitätsklinikum Münster, Münster, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Claudia FrickClaudia Frick
Claudia Frick
MMMarcus Müller
Marcus Müller
UWUte Wank
Ute Wank
ATAnke Tropitzsch
Anke Tropitzsch
BKBenedikt Kramer
Benedikt Kramer
HLHubert Löwenheim
Hubert Löwenheim

1 May 2006 in Journal of Neuropathology & Experimental Neurology
Verified
Journal Article
Open access
PDF file
MMMarcus Müller
Marcus Müller
MSMarkus Stenner
Markus Stenner
KWKarin Wacker
Karin Wacker
ERErich B. Ringelstein
Erich B. Ringelstein
WHWilliam F. Hickey
William F. Hickey
RKReinhard Kiefer
Reinhard Kiefer
Macrophages are intimately involved in the pathogenesis of inflammatory neuropathies. The contribution of resident endoneurial macrophages is unknown since their differentiation from infiltrating macrophages is difficult due to missing cellular markers. Previous studies demonstrated the participation of resident macrophages in Wallerian degeneration and the pathogenesis of hereditary neuropathies. The question arises whether resident macrophages are involved in experimental autoimmune neuritis (EAN) where they could contribute to immunosurveillance and antigen presentation. To address this question we used bone marrow chimeric rats, allowing the differentiation between resident and hematogenous cells. Immunohistochemistry and in situ hybridization were applied on to identify and characterize resident macrophages in terms of morphological features, expression of activation markers, proliferation, phagocytosis, and MHC-II expression. Endoneurial macrophages of resident origin were detectable at all stages of disease with a contribution of at least 27% of the total macrophages. They appeared activated by morphological and immunohistochemical criteria and proliferated early. MHC-II-positive resident macrophages were observed that had phagocytosed myelin. These results demonstrate that the macrophage response in EAN is partly of intrinsic origin. The rapid activation and proliferation of resident endoneurial macrophages points toward an active role of these cells in inflammatory peripheral nerve disease, especially early in disease.

27 March 2008 in Glia
Verified
Journal Article
Closed access
PDF file
MMMarcus Müller
Marcus Müller
KWKarin Wacker
Karin Wacker
DGDaniel Getts
Daniel Getts
ERErich Bernd Ringelstein
Erich Bernd Ringelstein
RKReinhard Kiefer
Reinhard Kiefer

10 November 2020 in Human Mutation
Verified
Journal Article
Open access
PDF file
ARAboulfazl Rad
Aboulfazl Rad
TSThore Schade‐Mann
Thore Schade‐Mann
PGPhilipp Gamerdinger
Philipp Gamerdinger
GYGrigoriy A. Yanus
Grigoriy A. Yanus
BSBjörn Schulte
Björn Schulte
BVBarbara Vona
Barbara Vona
Alpha‐chain collagen molecules encoded by genes that include COL11A1 are essential for skeletal, ocular, and auditory function. COL11A1 variants have been reported in syndromes involving these organ systems. However, a description of the complete clinical spectrum is lacking, as evidenced by a recent association of autosomal dominant nonsyndromic hearing loss due to a splice‐altering variant in COL11A1, mapping the DFNA37 locus. Here, we describe two German families presenting prelingual autosomal dominant nonsyndromic hearing loss with novel COL11A1 heterozygous splice‐altering variants (c.652‐1G>C and c.4338+2T>C) that were molecularly characterized. Interestingly, the c.652‐1G>C variant affects the same intron 4 canonical splice site originally reported in the DFNA37 family (c.652‐2A>C) but elicits a different splicing outcome. Furthermore, the c.4338+2T>C variant originated de novo. We provide clinical and molecular genetic evidence to unambiguously confirm that COL11A1 splice‐altering variants cause DFNA37 hearing loss and affirm that COL11A1 be included in the genetic testing of patients with nonsyndromic deafness.

1 October 2015 in Journal of Neuroscience Methods
Verified
Journal Article
Open access
PBPeter Bako
Peter Bako
MBMohamed Bassiouni
Mohamed Bassiouni
AEAndreas Eckhard
Andreas Eckhard
IGImre Gerlinger
Imre Gerlinger
Claudia FrickClaudia Frick
Claudia Frick
MMMarcus Müller
Marcus Müller
Histological analysis of the cochlea is required to understand the physiological and pathological processes in the inner ear. In the past, many embedding techniques have been tested in the cochlea to find an optimal protocol that gives both good morphological and immunohistochemical results. Resins provide high quality cochlear morphology with reduced immunogenicity due to the higher polymerization temperature. We used Technovit 9100 New(®), a low temperature embedding system based on methyl methacrylate, on adult guinea pig and mouse cochleae to evaluate preservation of the morphology and maintenance of the antigenicity. Conventional toluidine blue staining, as well as immunohistochemical staining with a set of commonly used antibodies, showed highly preserved morphology and immunogenicity of decalcified adult guinea pig and mouse cochleae. We demonstrate both, well-preserved morphology and preservation of antigenicity, superior to other embedding techniques. Our results showed that the Technovit 9100 New(®) embedding system provided highly preserved morphology and immunogenicity with our protocol in adult guinea pig and mouse cochleae.

1 June 2014 in Toxicology Letters
Verified
Journal Article
Open access
ATAnke Tropitzsch
Anke Tropitzsch
HAHeinz Arnold
Heinz Arnold
MBMohamed Bassiouni
Mohamed Bassiouni
AMAndrea Müller
Andrea Müller
AEAndreas Eckhard
Andreas Eckhard
HLHubert Löwenheim
Hubert Löwenheim
Cisplatin is a widely used anti-cancer drug. Ototoxicity is a major dose-limiting side-effect. A reproducible mammalian in-vitro model of cisplatin ototoxicity is required to screen and validate otoprotective drug candidates. We utilized a whole organ culture system of the postnatal mouse inner ear in a rotating wall vessel bioreactor under "simulated microgravity" culture conditions. As previously described this system allows whole organ culture of the inner ear and quantitative assessment of ototoxic effects of aminoglycoside induced hair cell loss. Here we demonstrate that this model is also applicable to the assessment of cisplatin induced ototoxicity. In this model cisplatin induced hair cell loss was dose and time dependent. Increasing exposure time of cisplatin led to decreasing EC50 concentrations. Outer hair cells were more susceptible than inner hair cells, and hair cells in the cochlear base were more susceptible than hair cells in the cochlear apex. Initial cisplatin dose determined the final extent of hair cell loss irrespective if the drug was withdrawn or continued. Dose dependant otoprotection was demonstrated by co-administration of the antioxidant agent N-acetyl l-cysteine. The results support the use of this inner ear organ culture system as an in vitro assay and validation platform for inner ear toxicology and the search for otoprotective compounds.